银屑病生物制剂疗效与耐受性比较:更新的网状Meta分析
该更新的网状Meta分析纳入62项随机对照试验(31 899例参与者),比较11种NICE批准的生物制剂在10-16周时的疗效与耐受性。结果显示所有生物制剂均优于安慰剂或甲氨蝶呤, hierarchical聚类分析表明阿达木单抗、布罗达鲁单抗、 certolizumab pegol、古塞奇尤单抗、risankizumab、司库奇尤单抗、tildrakizumab和乌司奴单抗在短期高效与耐受性方面相当;英夫利西单抗和依奇珠单抗聚类一起,短期高效但耐受性相对较低,需谨慎解读。
要点
- 所有生物制剂在10-16周疗效均优于安慰剂或甲氨蝶呤。
- 多数生物制剂在短期疗效与耐受性上聚类相近,无单一最佳药物。
- 英夫利西单抗和依奇珠单抗短期高效但耐受性相对较低。
核心结论
- 大多数生物制剂在短期疗效和耐受性上聚类相近,未识别出单一最佳药物。
- 治疗决策需结合长期疗效、实效数据、安全性、给药方案和药品购置成本。
研究设计与样本
- 更新的频率学派网状Meta分析,检索MEDLINE、PubMed、Embase和Cochrane数据库至2018年9月7日。
- 纳入62项随机对照试验,共31 899例参与者,比较11种NICE批准的生物制剂与甲氨蝶呤或安慰剂。
主要发现
- 所有生物制剂在10-16周疗效均优于安慰剂或甲氨蝶呤。
- hierarchical聚类分析显示阿达木单抗、布罗达鲁单抗、certolizumab pegol、古塞奇尤单抗、risankizumab、司库奇尤单抗、tildrakizumab和乌司奴单抗在短期高效与耐受性方面相当。
- 英夫利西单抗和依奇珠单抗聚类一起,短期高效但耐受性相对较低,但网络内停药事件数少,需谨慎解读。
关键数值与推荐
- 疗效指标包括PASI 90或PGA 0/1、PASI 75、DLQI改善;耐受性指标为因不良事件停药,评估时间10-16周。
- 所有生物制剂在10-16周疗效均优于安慰剂或甲氨蝶呤。
- hierarchical聚类分析将多数生物制剂归为短期高效且耐受性相当,英夫利西单抗和依奇珠单抗归为高效但耐受性相对较低。
临床怎么用
- 临床选择生物制剂时需综合考虑短期疗效与耐受性聚类结果,以及长期疗效、实效、安全性、给药方案和成本。
- 英夫利西单抗和依奇珠单抗的耐受性相对较低需谨慎解读,因网络内停药事件数少。
局限性
- 网络内因不良事件停药事件数少,英夫利西单抗和依奇珠单抗耐受性相对较低的发现需谨慎解读。
- 结果需结合长期疗效、实效数据、安全性、给药方案和药品购置成本进行解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The rapid expansion of psoriasis biologics has led to an urgent need to understand their relative efficacy and tolerability to inform treatment decisions better and, specifically, to inform guideline development. OBJECTIVES: To update a 2017 meta-analysis on the comparative efficacy and tolerability of biologic treatments for psoriasis. METHODS: We searched the MEDLINE, PubMed, Embase and Cochrane databases for randomized controlled trials (RCTs), published up to 7 September 2018, of 11 licensed, NICE-approved biologics targeting tumour necrosis factor (adalimumab, etanercept, infliximab, certolizumab pegol), interleukin (IL)-12/IL-23p40 (ustekinumab), IL-17A (secukinumab, ixekizumab), IL-17RA (brodalumab) and IL-23p19 (guselkumab, tildrakizumab, risankizumab). A frequentist network meta-analysis ascertained direct or indirect evidence comparing biologics with one another, methotrexate or placebo. This was combined with hierarchical cluster analyses to consider efficacy (≥ 90% improvement in Psoriasis Area and Severity Index (PASI 90) or Physician's Global Assessment 0 or 1; PASI 75; Dermatology Life Quality Index improvement) and tolerability (drug withdrawal due to adverse events) outcomes at 10-16 weeks, followed by assessments of study quality, heterogeneity and inconsistency. RESULTS: We identified 62 RCTs presenting data on direct comparisons (31 899 participants). All biologics were efficacious compared with placebo or methotrexate at 10-16 weeks. Hierarchical cluster analyses revealed that adalimumab, brodalumab, certolizumab pegol, guselkumab, risankizumab, secukinumab, tildrakizumab and ustekinumab were comparable with respect to high short-term efficacy and tolerability. Infliximab and ixekizumab clustered together, with high short-term efficacy but relatively lower tolerability than the other agents, although the number of drug withdrawal events across the network was low, so these findings should be treated with caution. CONCLUSIONS: Using our methodology we found that most biologics cluster together with respect to short-term efficacy and tolerability, and we did not identify any single agent as 'best'. These data need to be interpreted in the context of longer-term efficacy, effectiveness data, safety, posology and drug acquisition costs when making treatment decisions.
引用
- Mahil SK, Ezejimofor MC, Exton LS, et al. Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta-analysis. Br J Dermatol. 2020. PMID: 32562551. doi:10.1111/bjd.19325
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。